This company listing is no longer active
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Nanexa AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.70 |
| 52 Week High | SEK 1.20 |
| 52 Week Low | SEK 0.64 |
| Beta | 1.45 |
| 11 Month Change | 0% |
| 3 Month Change | 7.98% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -41.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| NANEXA BTA | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | 0% | 1.1% | 0.6% |
| 1Y | n/a | -2.6% | 14.7% |
Return vs Industry: Insufficient data to determine how NANEXA BTA performed against the Swedish Medical Equipment industry.
Return vs Market: Insufficient data to determine how NANEXA BTA performed against the Swedish Market.
Price Volatility
| NANEXA BTA volatility | |
|---|---|
| NANEXA BTA Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 7.0% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in SE Market | 12.8% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: NANEXA BTA has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine NANEXA BTA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 19 | David Westberg | www.nanexa.com |
Nanexa AB (publ) operates as a nanotechnology drug delivery company. It operates PharmaShell, a nanobased drug delivery platform that is an atomic layer deposition. The company also develops NEX-18, which drives the development of a PharmaShell that targets myelodysplastic Syndrome and Acute Myeloid Leukemia; NEX-20 for the treatment of multiple myeloma; and NEX-22 for the treatment of type 2 diabetes.
Nanexa AB (publ) Fundamentals Summary
| NANEXA BTA fundamental statistics | |
|---|---|
| Market cap | SEK 61.91m |
| Earnings (TTM) | -SEK 43.18m |
| Revenue (TTM) | SEK 51.64m |
1.2x
P/S Ratio-1.4x
P/E RatioIs NANEXA BTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NANEXA BTA income statement (TTM) | |
|---|---|
| Revenue | SEK 51.64m |
| Cost of Revenue | SEK 27.34m |
| Gross Profit | SEK 24.29m |
| Other Expenses | SEK 67.47m |
| Earnings | -SEK 43.18m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Feb 21, 2024
| Earnings per share (EPS) | -0.71 |
| Gross Margin | 47.05% |
| Net Profit Margin | -83.62% |
| Debt/Equity Ratio | 2.9% |
How did NANEXA BTA perform over the long term?
See historical performance and comparison